Brain-health supplements: what the trials found

Walk down any pharmacy aisle and you will see bottles that promise a sharper memory and a younger brain. The marketing is confident. The evidence is not. Over the past two decades, researchers have run large, well-designed randomized trials on the most-marketed brain and memory ingredients. Most of those trials came back negative. This article reports what the studies found for ginkgo biloba, omega-3 fish oil, B vitamins, vitamin E, and multivitamins, and it flags the one result that looked different. Throughout, we report what the trials measured and leave the personal decisions to you and your clinician.

Ginkgo biloba: the big trial found nothing

Ginkgo is one of the most-studied memory supplements, and the largest trial is a clear null. The Ginkgo Evaluation of Memory (GEM) study enrolled 3,069 community-dwelling adults aged 75 and older. Participants took either 120 mg of ginkgo biloba extract twice a day or a matching placebo, and researchers followed them for a median of about six years (DeKosky et al., JAMA, 2008).

The result: ginkgo did not reduce the incidence of dementia or Alzheimer’s disease. The rates of new dementia were similar in the ginkgo and placebo groups. A separate GEM analysis also found that ginkgo did not slow the rate of cognitive decline over time (Snitz et al., JAMA, 2009).

A Cochrane systematic review of ginkgo for cognitive impairment and dementia reached a consistent conclusion, reporting that the evidence for a benefit is inconsistent and unreliable (Birks and Grimley Evans, Cochrane Database of Systematic Reviews, 2009).

Omega-3 fish oil: no cognitive benefit in a large trial

Fish oil is often sold as brain food, but a large randomized trial did not find a memory benefit. The Age-Related Eye Disease Study 2 (AREDS2) was designed to test eye supplements, and it included a cognitive-function substudy of 3,741 older adults with an average age in the early 70s. Participants were randomly assigned to take omega-3 fatty acids (DHA and EPA), lutein and zeaxanthin, both, or neither.

Over about five years of cognitive testing, the omega-3 supplements did not improve cognitive function compared with placebo (Chew et al., JAMA, 2015). The lutein and zeaxanthin arm also showed no cognitive benefit.

Observational studies that track people who eat more fish have sometimes reported better cognitive scores. That association is not the same as proof that a fish-oil pill protects the brain, and the randomized test did not confirm it.

B vitamins and homocysteine: mixed and mostly null

The theory was appealing, and the memory results have not followed. Higher blood levels of homocysteine, an amino acid, are linked to worse brain aging in observational studies. B vitamins (folic acid, B6, and B12) reliably lower homocysteine, so researchers tested whether that lowering would protect memory.

The results have been mixed and mostly disappointing. A meta-analysis that pooled 11 randomized trials with roughly 22,000 participants found that lowering homocysteine with B vitamins did not improve cognitive function (Clarke et al., American Journal of Clinical Nutrition, 2014). Some smaller studies, such as the VITACOG trial, reported that B vitamins slowed a marker of brain shrinkage on scans (Smith et al., PLoS One, 2010), but a brain-imaging signal is a surrogate, and it has not translated into a consistent memory benefit in larger trials.

Vitamin E: no clear memory benefit, and a safety flag at high doses

Vitamin E is an antioxidant, and antioxidants once looked like an obvious brain play. The prevention data did not deliver. For healthy older adults, vitamin E supplements have not shown a clear benefit for memory or for preventing cognitive decline.

There is a narrower finding worth stating precisely. In people who already had mild-to-moderate Alzheimer’s disease, one trial reported that high-dose vitamin E slowed functional decline compared with placebo (Dysken et al., JAMA, 2014). That is a treatment finding in diagnosed patients, not evidence that vitamin E prevents memory loss in healthy people.

High doses also carry a safety flag. A meta-analysis of 19 trials found that high-dose vitamin E, at 400 international units a day or more, was associated with a higher risk of death from any cause (Miller et al., Annals of Internal Medicine, 2005). That is a reason for caution with high-dose antioxidant pills, and it is a decision to discuss with a clinician.

The multivitamin outlier: a small, real signal

One result stands apart from the pattern, and it deserves to be reported with care. The COSMOS-Mind trial randomly assigned 2,262 older adults to a daily multivitamin (a standard commercial formula) or placebo and tracked cognition by telephone testing over three years. The multivitamin group showed a small but statistically significant benefit on global cognition compared with placebo (Baker et al., Alzheimer’s & Dementia, 2023).

A few points keep this in perspective. The effect was modest. It was measured on a global cognitive score, not on a single memory test, and a multivitamin is a broad micronutrient supplement, not a targeted memory pill. The finding needs replication and longer follow-up before anyone treats it as settled. It is a genuine positive signal in a field full of negative ones, and reporting it fairly means noting both the result and its limits.

When marketing outruns the evidence: the Prevagen case

Regulators have stepped in when memory claims lacked support. In 2017, the Federal Trade Commission and the New York Attorney General charged the marketers of Prevagen, a widely advertised memory supplement, with making deceptive claims that it improves memory and cognitive function (Federal Trade Commission, 2017). The complaint argued that the company’s own study did not support its advertising.

The case is a useful lens for the whole category. A confident television ad, a science-sounding ingredient, and a large sales figure are not evidence of a benefit. The trials above are the evidence, and for most of these products the trials are null. Broader prevention research points elsewhere: a Lancet Commission estimated that a set of modifiable risk factors, including hearing loss, high blood pressure, smoking, and physical inactivity, account for a large share of dementia risk, with supplements not on that list (Livingston et al., Lancet, 2020).

This article reports what randomized trials and expert reviews have found. It is not medical advice, and it does not recommend or discourage any specific product, dose, or plan. Supplements can interact with medications and with existing conditions, and the right choice depends on your own health picture. If you are weighing a brain-health supplement, or you are worried about your memory, bring these findings to a licensed clinician who knows your history and can help you decide.

Common questions

Does any supplement clearly prevent memory loss or dementia?

No supplement has strong randomized-trial evidence that it prevents dementia in healthy adults. Ginkgo, omega-3 fish oil, B vitamins, and vitamin E have all been tested in large trials and mostly showed no benefit. One trial found a small benefit from a daily multivitamin on global cognition (Baker et al., Alzheimer’s & Dementia, 2023), but that result needs replication and is not a proven memory cure.

If observational studies link fish or vitamins to better brain aging, why did the trials fail?

Observational studies compare people who already differ in many ways. People who eat more fish or take more vitamins often exercise more, smoke less, and see doctors more often, and those habits can drive better outcomes on their own. Randomized trials remove that confounding by assigning the supplement or a placebo at random. When the omega-3 and B-vitamin trials did that, the apparent benefit largely disappeared.

Is the vitamin E finding for Alzheimer’s a reason to take it?

That is a decision for a clinician. One trial reported that high-dose vitamin E slowed functional decline in people who already had mild-to-moderate Alzheimer’s disease (Dysken et al., JAMA, 2014). That is different from preventing memory loss in healthy people, where no clear benefit has been shown. High doses have also been linked to a higher risk of death from any cause (Miller et al., Annals of Internal Medicine, 2005), so it warrants a careful conversation with a doctor.

What does have evidence for protecting the brain as we age?

Large reviews point to lifestyle and medical factors rather than pills. The Lancet Commission on dementia highlighted modifiable risks such as high blood pressure, hearing loss, smoking, physical inactivity, and social isolation (Livingston et al., Lancet, 2020). Addressing those is where the strongest prevention evidence sits. Discuss your own risk factors with a clinician.